Patients with epilepsy carrying at least one CYP2C9*2 allele may have decreased phenytoin metabolism, increased plasma phenytoin concentration, and increased ADR occurrence compared with wild-genotype patients (6). Here, CYP2C9 is linked to epilepsy.